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Management of Head and Neck Melanoma 
James H F Shaw and Michael Fay 
Auckland Hospital, Great Mercury Island 
New Zealand 
1. Introduction  
The incidence of melanoma in New Zealand (NZ) is one of the highest in the world:  The 
rate in Caucasians is approximately 50 per 100,000,  while the incidence in the NZ Maori 
population and the NZ Polynesian population is much lower contributing 15% and 7% of 
the total number of melanoma reported annually (Shaw, 2008). The primary author has 
twenty-six years’ Consultant Surgical experience with melanoma surgery. Our database 
goes back to 1984 and includes 3,500 patients, of which 550 patients have been managed for 
head and neck melanoma. We have included all patients with either head and neck primary 
melanoma or regional melanoma involving cervical regional nodes or parotid nodes 
managed in the Auckland area 1984-2005. No patients have been excluded. These Head & 
Neck melanoma (H&NMM) data have never been published in the world literature.  
We reviewed our head and neck melanoma data base and this constitutes the basis of this 
study. 
2. Background & methods 
The head and neck area is a preferred site for melanoma; 9% of the body’s surface area but 
15% of the total melanoma distribution(Douglas & Shaw, 1987) 
The outcome is probably less favourable in the head and neck area than in limbs or trunk 
(Douglas & Shaw, 1987) (Fisher & O’Brien, 2002). In addition, some head and neck sites are 
less favourable than others for example scalp, mucosal lesions tend to be less favourable 
than facial lesions (Douglas & Shaw, 1987; Fisher & O’Brien, 2002),  further it is unclear 
whether melanomas from the trunk metastasising to cervical lymph nodes are more or less 
favourable than melanomas spreading to regional nodes with a head and neck primary. 
Over the past 20 plus years  for lesions < 1 mm in thickness we have used a 1 cm margin for 
lesions, > 2 mm thickness a 2 cm margin and for lesions between 1 and 2 mm thickness a 
margin of between 1 and 2 cm. The approach for thin lesions has been based on the work of 
Umberto Veronessi and colleagues (Veronessi et al, 1998),  while our approach for thicker 
lesions has been validated in a prospective study by Merion Thomas and colleagues 
(Thomas et al, 2004). 
Prior to the advent of sentinel node biopsy regional disease was treated with a therapeutic 
node dissection after positive fine needle aspirate cytology (FNA). Most commonly this was 
a selective neck dissection. Since the advent of sentinel node biopsy patients with a positive 
sentinel node have all been treated with either a selective or modified neck dissection 
depending upon the site of the primary lesion. After neck dissection virtually all patients 
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were offered radiotherapy and this was accepted by around half the patients. Nodal disease 
was classified N0 if no nodes were involved, N1 if one node was positive,  N2 if 2-3 nodes 
were involved,  and N3 if  4 or more nodes involved. 
Survival was calculated using Kaplan Myer analysis while comparison between patient 
groups was performed using Chi squared analysis. 
Questions asked of our data-base included assessment of : 
a. Anatomical-site,  sex,  and  primary thickness on outcome 
b. Signficance of local and regional recurrence on outcome 
c. Determine extent of neck dissection required as a function of primary anatomical site 
d. Determine effect of adjuvant radiation following neck-dissection on regional re-
recurrence and survival 
e. Assess the outcome for patients with primary site that is: 
i. outside head and neck area 
ii. desmoplastic subtype and 
iii. mucosal subtype 
3. Results 
3.1 Anatomical distribution and thickness of primary lesions 
The commonest H&N primary anatomical site was face (52%), followed by scalp (19%), neck 
(17%),  ear (9%), and mucosal lesions (3 %). 
37% of primary lesions were < 0.75 mm thick, 14% were 0.76-1.5 mm thick, 27% were 1.5 – 
4.0 mm thick, and 23% were > 4.0 mm thick. 
Predictably, as in other parts of the body, the thickness of the primary lesion governed 
outcome see Figure 1. 
 
 
Fig. 1. Effect of Primary Thicknesses on Survival – Auckland 
The sex incidence was higher in males than females and is summarised in Table 1: 
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Trunk primary lesions metastasising to cervical nodes, and scalp lesions, were significantly 
more common in males ( p<0.05,  and p<0.03 respectively).  Ear lesions were almost twice as 
common in males as in females. 
 
 Male Female Ratio
Face 140 126 1.1
Neck 49 40 1.2
Ear 28 15 1.9
Trunk 15 4 3.8*
Scalp 75 10 7.5 **
Total 307 195 1.6
Table 1. Sex Incidence Head & Neck Melanoma - Auckland 
The effect of anatomical site on survival is shown in fig 2. Survival for facial lesions is 
significantly better than for neck lesions (p<.05) and for Scalp & ear lesions (p<.01).  
 
 
Fig. 2. Effect of Anatomical Site on Survival - Auckland 
Local recurrence (LR) occurred in 5% for patients with facial, neck and ear lesions versus 13% 
for scalp lesions (p < 0.05) and 50% for mucosal lesions (p < 0.01). Local recurrence became 
progressively more common with increasing thickness of the primary lesion: see Table 2. 
 
Thickness   mm % Local Recurrence Fraction
< 0.76 5% 8/168
0.76 – 1.5 11% 7/62
1.5 – 4.0 10% 11/112
> 4 20% 20/99
Overall 10% 46/441
Table 2. Effect of Thickness on Local Recurrence – Auckland  
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The pie graph (Fig 3) outlines the most likely reasons for local recurrence and their relative 
frequencies. 
 
Fig. 3. Factors Associated with 46 Local Recurrences - Auckland 
Local recurrence had a major impact on outcome in particular there was a significant 
increase in both the development of regional disease and also death from disease in those 
patients who developed LR compared with those who did not develop LR. see Table 3 
 
No Local Recurrence Local Recurrence 
Regional Nodes    26%  (97/425) Regional Nodes   46%*21/46*** 
Dead of Disease      25% (99/425) Dead of Disease   72%***  (33/46)**** 
Table 3. Local Recurrent & Outcome - Auckland 
The impact on survival of either local recurrence or regional recurrence was almost 
identical: see Figure 3.  
Regional disease was a function of thickness of the primary with 5% of patients developing 
regional disease with primary lesions < 0.75 mm. 25% of patients with primary lesions 0.76 – 
1.5 mm thickness developed regional disease and 35% of patients with melanomas over 1.5 
mm thickness developed regional disease. 
The timing of regional disease was a function of the thickness of the primary melanoma.  
Patients who had regional disease at initial presentation had a mean primary thickness of 
over 6 mm,  while patients who presented with progressively thinner primary lesions 
developed regional disease progressively later. see Table 4. 
 
Timing of Nodes 10 Thickness No of Nodes
@  Diagnosis 6.2 +/- 1.2 mm 2.1 
@   1-12 mths 2.8 +/- 0.4 mm 3.1 
@   12-48 mths 1.9 +/- 0.3 mm 2.8 
@   48 mths + 1.3 +/- 0.5 mm 2.2 
Table 4. Timing of Nodal Disease v 10  Thickness - Auckland  
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Fig. 3. Influence Local or Regional Recurrence on Survival - Auckland 
Survival following the diagnosis of regional disease was not influenced by disease free 
interval.  Although patients who had longer disease free intervals between initial diagnosis 
and the development of regional disease lived longer overall, once regional disease occurred 
the survival curves were not significantly different. See fig 4.  
The sites of Regional Disease as a Function of anatomical site of the primary lesion are 
summarised  in Table 5. The commonest sites of regional disease were level 2 nodes and 
parotid nodes.   
 
 Ear
n=14 
Face 
n=41 
Scalp 
n=39 
Neck
n=29 
Total 
n=123 
Parotid 64% 46% 31% 10% 38% 
Level 1 - 11% 7% 21% 9% 
Level 2 50% 29% 30% 90% 50% 
Level ¾ 7% 5% 20% 67% 25% 
Level 5 - 5% 28% 67% 25% 
Sub-occipital - - 8% 7% 4% 
Post-auricular - - 18% 7% 6% 
Table 5. Regional Disease v Anatomical Site of Melanoma – Auckland 
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Fig. 4. Survival Node +ve Patients from Onset of Regional Disease - Auckland 
3.2 Sentinel node studies 
Our Sentinel node data were in general accord with the above data regarding site of regional 
disease as a function of anatomical site of the primary melanoma with Level 2 and Parotid 
being the commonest sites of involvement. The unusual findings from these studies were: 
1. Bilateral or contralateral sentinel nodes in patients with lesion near the midline. 
2. The frequent incidence of multiple sentinel nodes (up to 5) 
3. The unpredictability of upper trunk lesions, for example spreading to contralateral 
Level 1. 
See Discussion for detailed analysis of sentinel data with world literature. 
3.3 Survival as a function of regional disease 
Patients without regional disease (stage No)  had 90% 5 year survival. Patients with only 
one node involved (stage N1), had 70% 5 yr survival, patients with stage N2 disease (2-3 
nodes involved) had 57% 5 yr survival, while  N3 patients with 4 or more nodes involved 
had 37%  5 yr survival. See Fig 5 
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Fig. 5. Stage of Regional Disease & Survival – Auckland 
3.4 Regional failure after neck dissection and the impact of radiation 
Regional failure was dependent on the N status of the neck. The rate of failure in patients 
with N1 disease was 5%, N2 disease 17% and N3 disease 22%. These rates of regional failure 
were all decreased with radiation and these reached statistical significance for patients with 
N3 disease and for regional disease overall. See Table 6. 
 
 % Failure no RT %  Failure with RT 
N1 11%         1/19 3%            1/31 
N2 25%         4/16 9%            2/22 
N3 38%        8/21 10%*         2/20  p < .04 
Overall 28%        13/46 7%***        5/71  p < .002 
Table 6. Influence of RT on Recurrence after Neck Dissection 
Although adjuvant radiation significantly decreased regional recurrence after neck 
dissection adjuvant radiation had no impact on survival: The Kaplan Meyer curves for 
survival after neck dissection alone versus neck dissection with radiation the curves were 
virtually super-imposed. See Fig 6 
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Fig. 6. Survival after neck dissection with and without Adjuvant radiation 
3.5 Less common situations 
3.5.1 Primary site unknown 
There were nine patients in this group all with stage N2 or N3 disease with a 35% 5 year 
survival which was virtually identical when compared with the 5 year survival for the 
group of patients with N2 and N3 disease who had a  known primary. 
3.5.2 Cervical regional disease from primary site on trunk 
There were 19 patients in this group, 14 had axillary and neck disease, 5 had neck disease 
alone. The mean number of nodes involved was was 11 (range 3-48). Neck Levels most 
commonly involved were: 
Level 5:  14 patients 
Level 4:   6 patients 
Level 3:  4 patients 
Level 1 or 2:  4 patients (including 1 patient with contralateral Level 1 disease) 
The outcome was very poor with 15/19 patients dead of disease at five years. See Fig 7 
3.5.3 Desmoplastic neurotropic melanoma 
There were 19 patients in this group. The lesions were thick with a mean thickness of 3.5 
mm. When the desmoplastic patient group were compared with patients with equivalent 
thickness lesions that were not desmoplastic: the local recurrence rate was higher in the 
desmoplastic group at 26% versus 7% (p < 0.04), while regional recurrence was lower in the 
desmoplastic group at 22% versus 47%. Death from disease was virtually identical in the 
two groups See Table 7. 
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Fig. 7. Survival of Patients with Trunk Primary versus primary lesion in the Head and Neck 
 
   Non Desmoplastic   Desmoplastic
Median Thickness         3.5 mm     4.1 mm 
Local Recurrence         7%   (20/261)    26%***     (9/19)  
Regional Nodes        47%* 107/261)    22%* p.06   (4/19) 
Dead of Disease        41%  (8/19)   42%       (95/261) 
Table 7. Desmoplastic v Non-Desmoplastic Melanoma – Auckland - Stratified for Equivalent 
Thickness 
3.5.4 Mucosal melanoma 
There were 14 patients in this group. The commonest sites were conjuntival, oral and nasal. 
There were poor outcomes here even for very thin lesions. Seven of the 14 patients 
developed local recurrence and 5/14 were dead of disease at 5 years despite a mean 
thickness of only  .3 mm.  
4. Discussion 
Our study is one of the largest studies of Head & Neck melanoma reported from a single 
centre.  The single greatest experience is however from the Sydney Melanoma Unit (De Wilt 
et al, 2004; Fisher & O’Brien, 2002; Thompson et al, 2005), and we have compared and 
contrasted our experience with theirs along with various centres worldwide. 
The data from Fisher S.R & O’Brien, C.J., 2002 are similar to ours with respect to anatomical 
site,  sex-incidence. In addition outcome versus anatomical site were similar to reports of 
others with face and neck lesions  having a more favourable outcome than scalp and ear. In 
addition the reason for these differences is largely explained on the basis of the face & neck 
lesions being thinner and therefore having a better outcome. Further,  although H&NMM 
www.intechopen.com
 
Treatment of Metastatic Melanoma 38
was more common in males the two sites where the incidence was almost the same for 
males and females  (Face and Neck) the outcome was better. We have previously shown that 
for melanoma overall when all sites are pooled the incidence in males and females is similar 
(Jones et al, 1999) and that overall males tend to have poorer outcomes than females 
especially older males (Jones et al, 1999; Shaw, 2008). Trunk and scalp lesions were 
significantly more common in males in our study:  we have previously shown the highest 
incidence of melanoma in males is on the back (Jones et al, 1999), Scalp melanoma is most 
common in bald patients and there are more bald men than women (Douglas & Shaw, 1987; 
Jones et al, 1999). 
The outcome for patients with desmoplastic melanoma (DM) is similar to that reported by 
Quinn and colleagues from the Sydney Melanoma Unit (Quin et al, 1998). In particular DM 
is associated with a relatively high incidence of LR coupled with a relatively low incidence 
of regional disease and when compared to non DM melanoma patients a similar risk of 
death. The relatively low rate of regional disease has some implications when considering 
the performance of sentinel node studies in patients with DM. Our data indicating that the 
outcome of patients with regional disease and primary site unknown is  similar to patients 
with regional disease and primary site known when stratified for similar stage of regional 
disease are in general agreement with the literature (Santini et al, 1985). 
Local recurrence (LR) in H&NMM has been reported to be more common than for limb 
melanomas (Douglas & Shaw, 1987; Jones et al, 1999; Ng et al, 2001). Our current findings 
are in agreement with this in a general sense, with the pie chart summarising the individual 
main causative factors,  namely thickness of the primary,  inadequate margin,  unfavourable 
histological sub-type.  We have previously documented  the effect of tumour thickness and 
inadequate margin on local recurrence (Ng et al, 2001). In addition the studies by Balch and 
colleagues (Balch et al, 2001) have highlighted that tumour thickness is very reliable and an 
independent predictor of both recurrence and survival.  
One sub-group where this rule of thickness being a reliable predictor of outcome is not 
useful is in  patients with mucosal melanoma; the  highest incidence of which is in the head 
and neck region (Tomicic & Wanebo, 2003). In our patients despite the medial thickness 
being only 1.3 mm the rates of recurrence and death from disease were markedly higher 
than for non- mucosal lesions of similar thickness. A variety of authors have underlined the 
poor prognosis associated with mucosal melanoma irrespective of either conservative or 
radical treatment involving surgery alone or combined with radiation (Tomicic & Wanebo, 
2003),  but the fact that even very thin lesions tend to recur appears to be relatively under-
reported. 
The implications of LR are substantial with approximately double the incidence of regional 
disease and approximately a three- fold risk of dying of melanoma. Further, the impact of 
LR and regional recurrence on survival were virtually identical. These findings are similar 
to those reported by O’Brien and colleagues ( Fisher & O’Brien, 2002) 
The regional nodes of significance when managing H&NMM are outlined in Fig 8. See 
below: In particular the nodes as classified by Memorial Sloan Kettering Cancer Centre 
(Shah et al., 1991) involving levels 1-5,  along with intra-parotid nodes coupled with the 
post-auricular nodes and the Sub-occipital nodes highlighted by the SMU (De Wilt et al, 
2004). In addition the axillary nodes are important especially for upper trunk lesions and 
lower neck lesions.  The importance of primary lesions from trunk regional to the neck,  and 
neck lesions regional to the axilla(e) has been relatively understudied but following the 
widespread use of sentinel node studies a far better understanding of H&N regional 
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lymphatics has been developed,  especially by Morton and colleagues at the John Wayne 
Cancer Centre (Morton et al, 2006) and Thomson and colleagues in Sydney Australia (De 
Wilt et al., 2004; Thompson et al., 2005). 
 
 
Fig. 8. Surgical Lymphatic Anatomy 
Timing of regional failure in our study was a function of primary tumour thickness with 
patients who had regional disease at initial presentation had a mean primary thickness of 
over 6 mm, while progressively thinner primary lesions went on to be associated with 
region disease of several years: 3 mm lesions tending to recur regionally inside 1 yr,  2mm 
lesions recurring regionally most commonly in 1-4 yrs,  and lesions 1-2 mm thick recurring 
most commonly later than 4 yrs. These findings are similar to those reported by O’Brien and 
Fischer (Fisher & O’Brien, 2002) and underline the capacity of even relatively thin 
melanomas to recur many years after initial diagnosis (Thompson et al., 2005). These finding 
also fit well  with the findings of Balch and colleagues in 2001 (Balch et al., 1985). After 
analysing 10 yr survival data for over 15,000 melanoma patients with lesions in all 
anatomical sites, the 10 yr mortality increased steadily as a smooth curve as a function of 
primary thickness from approximately 20% for 1 mm lesions through to 70% mortality for 
lesions 10 mm thick. See Fig 9 below 
For some malignancies disease free interval is an important prognostic factor (Fisher Fisher 
& O’Brien, 1998),  however for melanoma the situation is less clear (Thompson et al., 2005).  
In our study although patients who developed regional progressively further along the 
course of their disease had a relative long absolute survival,  once regional disease occurred 
the survival data curves from that time on were not significantly different between the 
various groups.  
One very important but contentious issue in the surgical  management of H&NMM patients 
is the extent of neck dissection which should be performed for regional disease as a function 
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of the anatomical site of the primary melanoma. Shah and colleagues in 1991 (Shah et al., 
1991) concluded that virtually all neck nodal levels along with the parotid nodes should be 
dissected in virtually all patients with H&NMM. Their data were based on therapeutic neck 
dissections for FNA diagnosed palpable regional disease. Their data are presented in 
modified format in Table 8 
 
 
Table 8. Regional H& N Melanoma v Anatomical Site, Shah et al.,  Amer J Surg 1991 
From the Shah data (Shah et al., 1991) one would conclude that virtually all patients with 
regional H&NMM require a Level 1-5 neck dissection and resection of parotid nodes. The 
exceptions being that posterior neck does not require parotidectomy (P) or dissection of 
Level 1, while anterior neck primary while requiring parotidectomy does not require 
dissection of Level 5 nodes,  and only occasionally will level 1 nodes be involved. 
Another major study addressing sites of regional disease as a function of anatomical 
primary melanoma site is that from the Sydney Melanoma Unit (SMU) (De Wilt et al., 2004). 
Their approach was a different one whereby 918 sentinel nodes were mapped in 362 
patients with H&NMM. A modified assessment of their data is presented in Table 9 below.  
The conclusions from the Sydney data are in general agreement with those of Shah and 
colleagues (Shah et al., 1991) whereby: 
1. Ear primary requires P,  and Levels 2-5 neck dissection,  but in contrast to Shah (Shah et 
al., 1991) level 1 would not require dissection 
2. Face primary requires P and Levels 1-4 ,  but in contrast to Shah (Shah et al., 1991) who 
found 20% of facial lesions involved L5 
3. Anterior scalp requires P and Levels 1-4 and possibly L5 also as 10% chance of 
involvement at SMU versus 57% involvement at MSKCC. 
4. Anterior neck requires Levels 1-5 but not P while Shah (Shah et al., 1991) found 33% 
had parotid involvement but no L5 disease 
Site of Nodal Involvement v Anatomical Site
Shah et al., Amer J Surg, 1991
27%20%30%-57%20%L5
41%27%25%28%50%12%L3,4
73%60%50%50%65%48%L2
27%47%-13%57%48%L1
83%29%-33%100%44%Parotid
EarPost 
Scalp
Post 
Neck
Ant 
Neck
Ant 
Scalp
Face
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Table 9. 918 Sentinel Nodes in 362 Melanoma Partients 
5. Posterior neck requires Levels 2-5 neck dissection with P only rarely required,  
concurring with while Shah (Shah et al., 1991) 
6. Posterior scalp requires levels 2-5 neck dissection with only 14% chance of P being 
required,  while Shah (Shah et al., 1991) found level 1 involved in 47% & and Parotid in 
29% of patients. 
The SMU data (14) also highlight the importance of the post-auricular and the Sub-occipital 
nodes especially for patients with Ear,  Scalp,  and posterior neck lesions. These were not 
assessed in the Shah data (Shah et al., 1991). 
Our own data agree with Shah (Shah et al., 1991) that: L1 does not usually require dissection 
for ear primary 
Our data are in agreement with SMU 14(15) : 
1. Face does not usually require dissection of L5 
2. L1 only rarely involved aside from face and neck primary lesions 
Our data  are in agreement with both MSKCC and SMU that neck lesions require a L2-5 
dissection and occasional inclusion for dissection of L1 and P depending on the site of the neck 
primary. Our data also highlight the importance of upper trunk lesions spreading to cervical 
nodes, and the fact that these lesions have an especially bad prognosis as most patients have 
N2 or N3 disease often with involvement of both cervical nodes and one or more axilla. The 
importance of trunk lesions involving neck nodes, and the associated bad prognosis has been 
relatively understudied in the literature. The principal levels involved by trunk primary 
melanoma are levels 5 followed by levels 4,  but occasionally levels 3,2,and 1 are involved. In 
addition for mid line lesions especially contralateral disease in unexpected sites may occur. In 
our study the outcome for trunk lesions that metastasised to cervical nodes either alone or in 
combination with axillary disease is markedly worse than for acral lentigenous melanoma, a 
known poor prognosis subtype which we have reported on previously (Koea & Shaw, 1988) 
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In order to provide a guidline for management of the neck in H&NMM we have modified 
the figure from O’Brien and colleagues (O’Brien, 1999) to provide some general rules 
regarding extent of neck dissection as a function   of primary anatomical site. See Fig 9 
 
 
Fig. 9. Types of Neck Dissection v Site of Melanoma 
There are a number of  provisos to be incorporated with this figure based on our findings 
and those from SMU (15) and MSKCC (14). These include: 
1. The risk of contralateral and bilateral regional disease with primary melanomas close to 
midline 
2. Level 1 is not often involved but occasionally may be  involved from as far away as 
posterior trunk and rarely bilateral 
3. Trunk lesions may require dissection of more than levels 4 and 5,  and involvement of 
one or both axillae must be excluded either by sentinel node study or imaging 
Results predicting regional disease levels as a function of anatomical site of primary may be 
different when data from sentinel node studies are compared with studies from therapeutic 
neck dissection data.  Also the extent of the neck dissection performed is also important for 
example;  in our study selective dissection was  frequently used in our  patients whereas in 
the Shah (Shah et al., 1991) data many patients underwent either conservative or radical 
neck dissection. In addition spread of melanoma cells along involved lymphatic channels 
may be different compared to the distribution of tracer as part of a sentinel node study in a 
clinically uninvolved neck. 
Survival as a function of extent of regional disease in our study is similar to what has been 
reported by others (Balch et al., 2001; Fisher & O’Brien, 2002; O’Brien,  1999). One common 
finding across centres is the dramatic drop-off in survival between N1 –N2 disease and N3 
disease. The reason for this being that the maximum number of nodes involved in N2 patients 
is 3 while some patients with N3 disease may have 20 or more nodes involved. See Table 10 
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Table 10. Regional Disease 5y Survival 
NZ:  New Zealand 
UAB:  University of Alabama 
Duke: Duke University 
MDA: MD Anderson Cancer Clinic, Texas 
In more detail the results of O’Brien and others (20) are summarised in Table 11 below: 
 
 
Table 11. Neck Dissection for Melanoma – (O’Brien et al., 1992) 
The role of adjuvant radiation to minimise recurrence after neck disease is debated in the 
literature. We offered the majority of patients adjuvant radiation while many clinicians offer 
radiation only for patients with multiple nodes or if extra-nodal spread is present (eg 20). 
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While the role of adjuvant radiation will only be totally resolved by a prospective 
randomised study some important findings emerge from our data. Firstly we were able to 
show a significant reduction in recurrence in patients who received adjuvant radiation,  
especially those with N3 disease. O’Brien (O’Brien et al., 1997) was also able to demonstrate 
a reduction in recurrence but this fell short of statistical significance (just). Our overall re-
recurrence rate of 28% in patients who did not receive adjuvant radiation is similar to the 
figure reported by O’Brien et al (O’Brien et al., 1997) and lower than many reports (O’brien 
et al., 1997). The dramatic decrease in recurrence in our patient both with N3 disease and 
regional disease overall is in agreement with the findings of Ang and colleagues (Ang et al., 
1994) from the MD Anderson unit in Texas. Ang and colleagues (Ang et al., 1994) were able 
to demonstrate a dramatic reduction in recurrence when  neck dissection was followed with 
adjuvant radiation compared with historic control data where surgery alone was used.  
Incidently they were also able to demonstrate that adjuvant radiation also reduction in 
recurrence following excision of prognostically unfavourable primary melanomas. For many 
years melanoma was considered to not be a radio-responsive tumour but this is now largely 
refuted (Mendenhall et al., 2008). The fact that adjuvant radiation decreased regional 
recurrence in our study while not influencing survival makes good sense from the surgical 
oncology standpoint. Adjuvant radiation is well known to minimise recurrence following 
neck dissection for squamous cell carcinoma (Fisher & O’Brien, 1998), and adjuvant 
radiation has been shown to minimise recurrence following anterior resection for rectal 
cancer (Fisher & O’Brien, 1998), and also minimise recurrence in some patients following 
surgery for Breast cancer,  but in most of these circumstance this decrease in recurrence does 
not  translate into improved survival. 
We have not presented data addressing complications in this present study. We have 
previously presented a comparison between our complications for node dissection in the 
neck, the axilla, and groin (Shaw & Rumball, 1990). In that study the complication rate 
following neck dissection and axillary dissection was similar and in both sites was markedly 
lower than following neck dissection. In addition the complications associated with the 
addition of adjuvant  radiation was lower in the neck than in the two other sites.  
5. Conclusions and recommendations 
1. The head and neck area is a preferred site for melanoma and has an unfavourable 
outcome in comparison to the rest of the body with respect to local recurrence and 
death from disease.  
2. There is a complex lymphatic system and both the performance of  sentinel node 
studies in the head and neck area and their analysis is more complex than in the trunk 
or limbs. Unpredicted sites of sentinel nodes are more common in the head & neck 
region than in the rest of the body. 
3. The timing of regional disease in H&NMM is important. Patients who had palpable 
regional disease at the time of initial presentation had an average primary thickness 
over 6 mm. Patients with progressively thinner primary lesions developed regional 
disease over subsequent years with the general rule being the thicker the primary the 
more quickly regional disease developed. Many of these patients were assessed prior to 
the use of sentinel node mapping and this will probably detect patients likely to recur 
especially in the first year after initial diagnosis of melanoma. Prolonged disease-free 
interval does not appear to be a favourable prognostic factor once regional disease has 
occurred. 
www.intechopen.com
 
Management of Head and Neck Melanoma 45 
4. Management of regional disease can often be accomplished using a selective neck 
dissection, the regional beds requiring resection can be assessed as a function of the 
primary site of the melanoma. In particular: 
a. For anterior scalp and face parotidectomy plus levels I-IV neck dissection. 
b. For coronal lesions including scalp and ear parotidectomy and  levels I-V neck 
dissection. 
c. For posterior scalp and posterior neck level II-V neck dissection.  
d. For trunk lesions with cervical regional disease Level 4 & 5 neck dissection is 
appropriate, often in association with one or more axillary dissections.  
e. Recommendations for sites of regional disease that should be resected for various 
primary melanoma sites are summarised in Fig 7. It is important to note that this is 
just a guideline as sites of regional disease are unpredictable. In particular upper 
back lesions involving cervical nodes can occasionally involve as far away as level 
1, while primary  lesions close to the midline (either head and neck or upper trunk 
primary) have a tendency to involve either contralateral nodes or bilateral nodes. 
d. The post -auricular nodes and sub- occipital nodes have to be considered in for 
patients with posterior scalp, coronal scalp and ear lesions and to a lesser extent 
with patients with posterior neck lesions. 
5. Desmoplastic melanoma, mucosal melanoma, and melanoma from trunk metastasising 
to neck have a relatively poor prognosis. Desmoplastic lesions tend to have relatively 
low rates of regional disease and relatively high rates of local recurrence resulting in 
survival similar to non-desmoplastic melanomas. Trunk melanomas metastasising to 
the neck usually represent N3 disease (occasionally N2) as a result of one or more 
axillary nodal beds also being involved. In addition trunk lesions, especially those close 
to the mid-line are one of the least  predictable in terms of where they are likely to 
spread in the neck. Further, while outcome for most melanomas is a function of primary 
melanoma thickness the exception to this rule is mucosal melanoma where even thin 
lesions are often lethal. 
6. Adjuvant radiation after neck dissection appears to minimises recurrence in the neck 
but does not appear to impact on survival. A prospective trial would be required to 
clarify this for certain. 
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